Literature DB >> 24166234

Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.

Christian G Reich1, Patrick B Ryan, Martijn J Schuemie.   

Abstract

BACKGROUND: A systematic risk identification system has the potential to test marketed drugs for important Health Outcomes of Interest or HOI. For each HOI, multiple definitions are used in the literature, and some of them are validated for certain databases. However, little is known about the effect of different definitions on the ability of methods to estimate their association with medical products.
OBJECTIVES: Alternative definitions of HOI were studied for their effect on the performance of analytical methods in observational outcome studies.
METHODS: A set of alternative definitions for three HOI were defined based on literature review and clinical diagnosis guidelines: acute kidney injury, acute liver injury and acute myocardial infarction. The definitions varied by the choice of diagnostic codes and the inclusion of procedure codes and lab values. They were then used to empirically study an array of analytical methods with various analytical choices in four observational healthcare databases. The methods were executed against predefined drug-HOI pairs to generate an effect estimate and standard error for each pair. These test cases included positive controls (active ingredients with evidence to suspect a positive association with the outcome) and negative controls (active ingredients with no evidence to expect an effect on the outcome). Three different performance metrics where used: (i) Area Under the Receiver Operator Characteristics (ROC) curve (AUC) as a measure of a method's ability to distinguish between positive and negative test cases, (ii) Measure of bias by estimation of distribution of observed effect estimates for the negative test pairs where the true effect can be assumed to be one (no relative risk), and (iii) Minimal Detectable Relative Risk (MDRR) as a measure of whether there is sufficient power to generate effect estimates.
RESULTS: In the three outcomes studied, different definitions of outcomes show comparable ability to differentiate true from false control cases (AUC) and a similar bias estimation. However, broader definitions generating larger outcome cohorts allowed more drugs to be studied with sufficient statistical power.
CONCLUSIONS: Broader definitions are preferred since they allow studying drugs with lower prevalence than the more precise or narrow definitions while showing comparable performance characteristics in differentiation of signal vs. no signal as well as effect size estimation.

Entities:  

Mesh:

Year:  2013        PMID: 24166234     DOI: 10.1007/s40264-013-0111-1

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  15 in total

1.  Determining the area under the ROC curve for a binary diagnostic test.

Authors:  S B Cantor; M W Kattan
Journal:  Med Decis Making       Date:  2000 Oct-Dec       Impact factor: 2.583

2.  Misclassification and selection bias in case-control studies using an automated database.

Authors:  J M Evans; T M MacDonald
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-09       Impact factor: 2.890

3.  Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.

Authors:  Ryan M Carnahan; Kevin G Moores
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

4.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

5.  The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.

Authors:  Christian G Reich; Patrick B Ryan; Marc A Suchard
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 6.  Definition and classification of acute kidney injury.

Authors:  John A Kellum; Rinaldo Bellomo; Claudio Ronco
Journal:  Nephron Clin Pract       Date:  2008-09-18

7.  Bias due to misclassification in the estimation of relative risk.

Authors:  K T Copeland; H Checkoway; A J McMichael; R H Holbrook
Journal:  Am J Epidemiol       Date:  1977-05       Impact factor: 4.897

8.  The effects of misclassification on the estimation of relative risk.

Authors:  B A Barron
Journal:  Biometrics       Date:  1977-06       Impact factor: 2.571

9.  Assessment of case definitions for identifying acute liver injury in large observational databases.

Authors:  Aaron J Katz; Patrick B Ryan; Judith A Racoosin; Paul E Stang
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

Review 10.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

View more
  15 in total

1.  How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.

Authors:  Martijn J Schuemie; M Soledad Cepeda; Marc A Suchard; Jianxiao Yang; Yuxi Tian; Alejandro Schuler; Patrick B Ryan; David Madigan; George Hripcsak
Journal:  Harv Data Sci Rev       Date:  2020-01-31

2.  Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.

Authors:  Martijn J Schuemie; Rosa Gini; Preciosa M Coloma; Huub Straatman; Ron M C Herings; Lars Pedersen; Francesco Innocenti; Giampiero Mazzaglia; Gino Picelli; Johan van der Lei; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 3.  Desideratum for evidence based epidemiology.

Authors:  J Marc Overhage; Patrick B Ryan; Martijn J Schuemie; Paul E Stang
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.

Authors:  Paul E Stang; Patrick B Ryan; J Marc Overhage; Martijn J Schuemie; Abraham G Hartzema; Emily Welebob
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

5.  The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.

Authors:  Christian G Reich; Patrick B Ryan; Marc A Suchard
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  Authors' reply to Hennessy and Leonard's comment on "Desideratum for evidence-based epidemiology".

Authors:  J Marc Overhage; Patrick B Ryan; Martijn J Schuemie; Paul E Stang
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

7.  From Data Silos to Standardized, Linked, and FAIR Data for Pharmacovigilance: Current Advances and Challenges with Observational Healthcare Data.

Authors:  Vassilis Koutkias
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

8.  Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network.

Authors:  Carmen Ferrajolo; Preciosa M Coloma; Katia M C Verhamme; Martijn J Schuemie; Sandra de Bie; Rosa Gini; Ron Herings; Giampiero Mazzaglia; Gino Picelli; Carlo Giaquinto; Lorenza Scotti; Paul Avillach; Lars Pedersen; Francesco Rossi; Annalisa Capuano; Johan van der Lei; Gianluca Trifiró; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2014-02       Impact factor: 5.606

Review 9.  Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.

Authors:  Thomas J Moore; Curt D Furberg
Journal:  Drug Saf       Date:  2015-07       Impact factor: 5.606

10.  A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions.

Authors:  Ying Li; Patrick B Ryan; Ying Wei; Carol Friedman
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.